circle

INVESTORS & MEDIA

PRESS RELEASES

  • Webcast
    X Cantor Fitzgerald Global Healthcare Conference
    Oct 3, 2019 10:40 AM EDT

    Cantor Fitzgerald Global Healthcare Conference
    Oct 3, 2019 10:40 AM EDT
Date Title and Summary
Toggle Summary Cytokinetics Announces Receipt of FDA Feedback Regarding Reldesemtiv in Patients With SMA
Six Minute Walk Test Acceptable as Primary Efficacy Endpoint for Potential Registration Program SOUTH SAN FRANCISCO, Calif. , Jan. 22, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it has received feedback from the U.S.
Toggle Summary Cytokinetics to Announce Fourth Quarter Results on February 21, 2019
SOUTH SAN FRANCISCO, Calif. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report fourth quarter results on February 21, 2019 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a
Toggle Summary Cytokinetics Announces Initiation of Phase 1 Clinical Study of AMG 594, a Cardiac Troponin Activator
Advancement of Second Novel Mechanism Cardiac Sarcomere Activator Reinforces Leadership Position in Muscle Directed Pharmacology SOUTH SAN FRANCISCO, Calif. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first subject has been dosed in a Phase
Toggle Summary Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
THOUSAND OAKS, Calif. , SOUTH SAN FRANCISCO, Calif. , and SURESNES, France, Feb. 21, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that METEORIC-HF ( M ulticenter E xercise T olerance E valuation of O mecamtiv Mecarbil R elated to I
Toggle Summary Cytokinetics Reports Fourth Quarter 2018 Financial Results
Company Provides 2019 Financial Guidance and Expected Milestones Reduced Operating Expenses vs. 2018; Over Two Years of Cash Based on Current Burn Rate Interim Analysis for GALACTIC-HF on Track for 1H 2019 Results from FORTITUDE-ALS Expected in Q2 2019 SOUTH SAN FRANCISCO, Calif. , Feb.
Toggle Summary Cytokinetics Joins Global Initiative To Recognize International Rare Disease Day
SOUTH SAN FRANCISCO, Calif. , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Cytokinetics , Incorporated (Nasdaq: CYTK) today announced that it is standing with the European Organisation for Rare Diseases (EURORDIS) and the National Organization for Rare Disorders (NORD) to recognize Rare Disease Day®, an
Toggle Summary Cytokinetics Announces Presentation of Results From FORTITUDE-ALS at the American Academy of Neurology 71st Annual Meeting
SOUTH SAN FRANCISCO, Calif. , March 07, 2019 (GLOBE NEWSWIRE) -- Cytokinetics , Incorporated (Nasdaq: CYTK) today announced that results from FORTITUDE-ALS ( F unctional  O utcomes in a  R andomized  T rial of  I nvestigational  T reatment with CK-2127107 to  U nderstand  D ecline in  E ndpoints –
Toggle Summary Cytokinetics Announces Additional Results From COSMIC-HF to be Presented at ACC.19
SOUTH SAN FRANCISCO, Calif. , March 11, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from COSMIC-HF ( C hronic O ral S tudy of M yosin Activation to I ncrease C ontractility in H eart F ailure), a Phase 2 trial evaluating omecamtiv
Toggle Summary Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at ACC.19
No Difference in Treatment Effects of Omecamtiv Mecarbil in Patients with Heart Failure Irrespective of Atrial Fibrillation SOUTH SAN FRANCISCO, Calif. , March 18, 2019 (GLOBE NEWSWIRE) -- Cytokinetics , Incorporated (Nasdaq: CYTK) today announced that additional results from COSMIC-HF ( C hronic O
Toggle Summary Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis
Data Monitoring Committee Recommends Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure to Continue Without Changes THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. and SURESNES, France, March 20, 2019 (GLOBE NEWSWIRE) -- Amgen (NASDAQ: AMGN), Cytokinetics,
Toggle Summary Cytokinetics to Present at April Investor Conferences
SOUTH SAN FRANCISCO, Calif. , April 01, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK ) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to present a corporate update at the following investor conferences: H.C.
Toggle Summary Cytokinetics to Announce First Quarter Results on May 9, 2019
SOUTH SAN FRANCISCO, Calif. , April 25, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report first quarter results on May 9, 2019 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a conference
Toggle Summary Cytokinetics Announces Results of FORTITUDE-ALS, a Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS, Presented at American Academy of Neurology Annual Meeting
Trial Did Not Meet Statistical Significance for Primary Efficacy Analysis Change from Baseline in Percent Predicted SVC at Week 12 SVC Change from Baseline (All Active vs Placebo) ALSFRS-R Change from Baseline (All Active vs Placebo) Change from Baseline in ALSFRS-R Gross Motor Domain Patients on
Toggle Summary Cytokinetics to Hold Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, Calif. , May 08, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 15, 2019 at 10:30 AM Pacific Time at the Embassy Suites Hotel , located at 250 Gateway Boulevard in South
Toggle Summary Cytokinetics Reports First Quarter 2019 Financial Results
GALACTIC-HF Continues Following Interim Analysis for Futility;  METEORIC-HF Opened to Enrollment Phase 1 Data for CK-274 Expected in Q3 2019; Planning Underway for Potential Progression to Phase 2 FORTITUDE-ALS Demonstrates Patients on All Doses of Reldesemtiv Declined Less Than Patients on Placebo
Toggle Summary Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS
SOUTH SAN FRANCISCO, Calif. and WASHINGTON, May 30, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) and The ALS Association today announced the continuation of their partnership in the fight against ALS. Cytokinetics is renewing its Gold Level Sponsorship of the National Walks to
Toggle Summary Cytokinetics to Present at the JMP Securities Life Sciences Conference
SOUTH SAN FRANCISCO, Calif. , June 12, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK ) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to present a corporate update at the JMP Securities Life Sciences Conference on Wednesday, June 19,
Toggle Summary Cytokinetics Announces Preclinical Data for Reldesemtiv to be Presented at the 2019 Annual Cure SMA Conference
SOUTH SAN FRANCISCO, Calif. , June 24, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that two preclinical poster presentations on the addition of reldesemtiv to treatment with SMN upregulators ( nusinersen and SMN-C1, an analogue to risdiplam ) will be presented
Toggle Summary Cytokinetics Announces Preclinical Data For Reldesemtiv Presented at the 2019 Annual Cure SMA Conference
Two Studies Show Addition of Reldesemtiv to SMN-Directed Treatment Increases Muscle Force in Mouse Model of Spinal Muscular Atrophy SOUTH SAN FRANCISCO, Calif. , June 28, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data from two preclinical studies of
Toggle Summary Cytokinetics Announces Completion of Enrollment in GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
Clinical Trial Enrolled Over 8,200 Patients With Reduced Ejection Fraction in 35 Countries SOUTH SAN FRANCISCO, Calif. , July 15, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the completion of patient enrollment in GALACTIC-HF ( G lobal A pproach to L owering A
Toggle Summary Cytokinetics Announces Preclinical Data Relating to CK-3773274 to be Presented at the American Heart Association’s Basic Cardiovascular Sciences Scientific Sessions
SOUTH SAN FRANCISCO, Calif. , July 22, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that two preclinical poster presentations relating to CK-3773274 (CK-274) will be presented at the American Heart Association’s Basic Cardiovascular Sciences (BCVS) Scientific
Toggle Summary Cytokinetics Granted European Orphan Designation for Reldesemtiv for the Treatment of Spinal Muscular Atrophy
SOUTH SAN FRANCISCO, Calif. , July 23, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European Medicines Agency (EMA) has granted orphan medicinal product designation to reldesemtiv for the potential treatment of spinal muscular atrophy (SMA). The U.S.
Toggle Summary Cytokinetics Announces Publication of Preclinical Data Demonstrating Fast Skeletal Muscle Troponin Activator Improves Muscle Energetics
SOUTH SAN FRANCISCO, Calif. , July 24, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the publication of data in The Journal of Physiology demonstrating that a fast skeletal muscle troponin activator (FSTA) can decrease skeletal muscle fatigue by increasing the
Toggle Summary Cytokinetics to Announce Second Quarter Results on August 8, 2019
SOUTH SAN FRANCISCO, Calif. , July 25, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report second quarter results on August 8, 2019 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a
Toggle Summary Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the American Heart Association’s Basic Cardiovascular Sciences Scientific Sessions
Preclinical Studies Show CK-3773274 Produces Exposure Related Effects on Cardiac Contractility in Healthy Animals and Mouse Models of Hypertrophic Cardiomyopathy and Support Therapeutic Hypothesis for Onset of Action and Reversibility in the Clinical Setting Figure: CK-3773274 decreased fractional
Toggle Summary Cytokinetics Reports Second Quarter 2019 Financial Results
Completed Enrollment in GALACTIC-HF with More than 8,200 Heart Failure Patients Results from Phase 1 Study of CK-274 to be Presented at HFSA in September 2019 ; Phase 2 Clinical Trial Expected to Begin in Q4 SOUTH SAN FRANCISCO, Calif. , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated
Toggle Summary Cytokinetics and Cure SMA Renew Partnership to Advance Education and Awareness of SMA
ELK GROVE VILLAGE, Ill. and SOUTH SAN FRANCISCO, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Cure SMA and Cytokinetics (Nasdaq:CYTK) today announced the renewal of their partnership to increase education, awareness, public policy and fundraising for spinal muscular atrophy (SMA).
Toggle Summary Cytokinetics to Present at September Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to present a corporate update at the following investor conferences: 17 th Annual Morgan Stanley
Toggle Summary Cytokinetics Announces Presentations at the 23rd Annual HFSA Scientific Meeting
SOUTH SAN FRANCISCO, Calif. , Sept. 06, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced two poster presentations at the 23 rd Annual Heart Failure Society of America (HFSA) Scientific Meeting in Philadelphia . The posters will be presented on September 13, 2019
Toggle Summary Cytokinetics Announces Data From Phase 1 Study of CK-3773274 at the HFSA 23ʳᵈ Annual Scientific Meeting
Pharmacokinetic/Pharmacodynamic Relationship in Humans Similar to Preclinical Findings Planned Phase 2 Clinical Trial Design  Data Support Progression to Phase 2 Clinical Trial in Patients with Obstructive Hypertrophic Cardiomyopathy to Begin in Q4 2019 SOUTH SAN FRANCISCO, Calif., Sept.
Toggle Summary Cytokinetics Announces Second Annual Communications Fellowship Program Call for Proposals
Grants Support Community Engagement for Patient Advocacy Organizations Focused on Cardiovascular or Neuromuscular Diseases Deadline for Applications is November 15 th , 2019 SOUTH SAN FRANCISCO, Calif. , Sept. 25, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a
Toggle Summary Cytokinetics to Present at the Cantor Fitzgerald Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK ) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to present a corporate update at the Cantor Fitzgerald Global Healthcare Conference on Thursday,
Toggle Summary Cytokinetics Announces Additional Results From FORTITUDE-ALS to be Presented at the 18th Annual NEALS Meeting
SOUTH SAN FRANCISCO, Calif. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from FORTITUDE-ALS ( F unctional  O utcomes in a  R andomized  T rial of  I nvestigational  T reatment with CK-2127107 to  U nderstand  D ecline in  E
Toggle Summary Cytokinetics Announces Presentation of Additional Analyses From FORTITUDE-ALS at the 18th Annual NEALS Meeting
Faster Progressing Patients Who Received Reldesemtiv in the Trial Demonstrated Statistically Significant Differences in the Decline in ALSFRS-R Total Score   SOUTH SAN FRANCISCO, Calif. , Oct. 04, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced additional analyses